Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Capricor Therapeutics (CAPR) over the last 16 years, with Q3 2025 value amounting to $55843.0.

  • Capricor Therapeutics' Capital Expenditures rose 51063.97% to $55843.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 3976.05%. This contributed to the annual value of $1.2 million for FY2024, which is 1103.86% down from last year.
  • Latest data reveals that Capricor Therapeutics reported Capital Expenditures of $55843.0 as of Q3 2025, which was up 51063.97% from $287738.0 recorded in Q2 2025.
  • Capricor Therapeutics' 5-year Capital Expenditures high stood at $896007.0 for Q1 2025, and its period low was $9145.0 during Q3 2024.
  • Over the past 5 years, Capricor Therapeutics' median Capital Expenditures value was $347690.0 (recorded in 2023), while the average stood at $363928.8.
  • As far as peak fluctuations go, Capricor Therapeutics' Capital Expenditures skyrocketed by 143775.47% in 2022, and later crashed by 9660.66% in 2024.
  • Capricor Therapeutics' Capital Expenditures (Quarter) stood at $368671.0 in 2021, then soared by 88.26% to $694044.0 in 2022, then dropped by 19.51% to $558604.0 in 2023, then decreased by 12.5% to $488798.0 in 2024, then crashed by 88.58% to $55843.0 in 2025.
  • Its last three reported values are $55843.0 in Q3 2025, $287738.0 for Q2 2025, and $896007.0 during Q1 2025.